Hormone levels following surgical and medical castration: defining optimal androgen suppression
- PMID: 29111538
- PMCID: PMC6038162
- DOI: 10.4103/aja.aja_38_17
Hormone levels following surgical and medical castration: defining optimal androgen suppression
Conflict of interest statement
MLH and RHG are former employees of GTx, Inc, the sponsor of the clinical trial from which these data were derived. MTS and EYY have no competing interests to declare
References
-
- Nishiyama T. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature. Urol Oncol. 2014;32:38e17–28. - PubMed
-
- Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151–6. - PMC - PubMed
-
- Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989;10:232–74. - PubMed
-
- Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S45–50. - PubMed
-
- Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem. 1998;44:2178–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
